Successes

Therakind has

• secured agreement of a Paediatric Investigation Plan (PIP) for its first product, Buccolam™, an oromucosal (buccal) solution of midazolam hydrochloride for the rapid treatment of children suffering from acute epileptic seizures. A clinical study, sponsored by Therakind, was recently conducted in Germany and the authorised product is expected to be available in 2011.
• secured “fast track” marketing approval status from the MHRA (UK Medicines and Healthcare products Regulatory Agency) for its second product, a collaborative project with another UK pharma company, for paediatric pain control. Clinical trials are ongoing.
• a strong pipeline of further products, actively progressing with other partners to secure regulatory approvals.